

# the Global Retinal Pharmaceutical Market

View the Table of Contents of this 231-page report:

## INTRODUCTION

Scope  
Methodology  
About the Authors  
The Report at a Glance

## EXECUTIVE SUMMARY

Focus on the Most Common Retinal Diseases  
Retinal Pharmaceutical Products Market  
Leading Competitors' Revenues and Units  
Trends

## THE RETINA & RETINAL DISEASE

Retina  
Macula  
Fovea and Foveola  
Optic Disc & Optic Nerve  
Choroid  
Vitreous Humor  
Pars Plana  
Overview of Retinal Disease  
The Most Common Retinal Diseases  
Inherited Retinopathies  
Other Retinal Disorders  
Retinal Surgeries  
Addressing Vision Loss

## AGE-RELATED MACULAR DEGENERATION

Dry AMD  
Geographic Atrophy (GA)  
Statistics for GA  
Investigative Directions  
Neovascular AMD  
Statistics for Wet AMD  
Polypoidal Choroidal Vasculopathy  
Statistics for PCV  
AMD Risk Factors  
Aging  
Race  
Hereditary  
Smoking  
Diet & Nutrition  
Sun Exposure  
Symptoms of AMD  
Diagnosis of AMD  
Diagnostic Technologies  
AMD Treatments  
Laser Photocoagulation  
Pharmaceutical Therapies  
Anti-VEGFs  
Investigational Pharmaceuticals

## DIABETIC RETINOPATHY & DME

Diabetes  
Diabetic Retinopathy  
Nonproliferative DR  
Proliferative Diabetic Retinopathy (PDR)  
Statistics for Vision-Threatening DR  
Diabetic Macular Edema (DME)  
Statistics for Diabetic Macular Edema  
Increases in Diabetes, DR, and DME  
DR and DME Risk Factors  
Blood Glucose, Blood Pressure & Blood Lipids  
Race  
Glitazones & DME  
Diagnosis and Management  
DR and DME Treatments  
Laser Photocoagulation  
Vitreotomy  
Pharmaceuticals

## OTHER RETINAL DISEASES & CONDITIONS

RP and Other Inherited Retinopathies  
Treatment  
Statistics for RP & Other Inherited Retinopathies  
Other Retinal Diseases and Conditions  
Retinal Artery Occlusion  
Retinal Vein Occlusion  
Retinoblastoma

Epiretinal Membrane (ERM)  
Central Serous Chorioretinopathy (CSCR)  
Retinopathy of Prematurity (ROP)  
CMV Retinitis  
Infectious Inflammatory Chorioretinal Diseases  
Statistics for Other Retinal Diseases  
Retinal Holes, Tears and Detachments  
Statistics for Retinal Holes, Tears & Detachments

## EPIDEMIOLOGY OF RETINAL DISEASE

Epidemiology of AMD  
AMD by Category  
Epidemiology of Diabetic Retinopathy  
Diabetic Retinopathy by Category  
Epidemiology of Retinal Holes, Tears, Detachments, and Trauma  
Epidemiology of Inherited Retinopathies and Other Retinal Diseases

## PATIENT ECONOMICS AND REIMBURSEMENT

Causes of Blindness Globally  
Causes of Blindness Shift in Wealthy Nations  
Treatment Costs

## RETINA SPECIALISTS

Retina Training  
The Retina Specialty Worldwide  
Services and Reimbursement  
Diagnosing and Monitoring  
Intravitreal Injections  
Laser Photo-Activation  
Vitreotomy  
Repair of Retinal Detachments  
Laser Photocoagulation  
Location of Retinal Services  
Associations and Conferences  
Retina Societies  
Retina Meetings

## RETINA PHARMACEUTICALS ON THE MARKET

A Brief History  
VEGF Inhibitors  
Genentech/Roche's Lucentis  
Lucentis Gains Approval for ME due to RVO  
Lucentis for DME  
Lucentis for Additional Indications  
Lucentis' Safety  
The Business of Lucentis  
Genentech/Roche's Compounded Avastin  
Avastin and Ocular Non-AMD Indications  
Avastin's Safety  
The Business of Off-label Ophthalmic Avastin  
Lucentis/Avastin Controversy  
Rift over Compounding Pharmacies  
Controversy Continues to Flare  
CATT Compares Lucentis and Avastin  
EyeTech/Pfizer's Macugen  
Macugen's Safety  
The Business of Macugen  
Concerns about VEGF Inhibition  
Treatment Burden  
Long-term VEGF Inhibition  
Photodynamic Therapy  
QLT/Novartis' Visudyne Photodynamic Therapy  
PDT's Fluence Rate  
Visudyne PDT's Safety  
The Business of Visudyne PDT  
Combination Therapies  
Sample Combination Therapy Regimens  
Combo Therapies in Use Today  
Combo Therapy vs. Monotherapy in Wet AMD  
Ophthalmic Corticosteroids  
Corticosteroid Safety  
Alcon's Triescence  
Allergan's Trivaris  
Bristol-Myers Squibb's Compounded Kenalog  
Investigational Sustained-Release Triamcinolone Acetonide

Safety of TA  
Allergan's Ozurdex  
Ozurdex' Safety  
Other Ophthalmic Dexamethasone Use  
pSivida/Bausch & Lomb's Retisert  
Investigational Implant of Fluocinolone Acetonide  
Other Ophthalmic Corticosteroids  
Other Marketed Pharmaceuticals with Retinal Applications

## RETINA PHARMACEUTICALS PIPELINE

A Multiplicity of Approaches  
VEGF Inhibition  
Regeneron's VEGF-Trap-Eye  
Chengdu Kanghong Biotech's KH902  
Genzyme's sFLT01  
Other VEGF Inhibitors  
Kinase Inhibition  
GlaxoSmithKline's Pazopanib  
Alcon's AL-39324  
Other Investigational Kinase Inhibitors  
RNA Interference  
Quark/Pfizer's PF-04523655  
Other siRNAs  
Antisense Technology  
iCo Therapeutics' iCo-007  
Gene Signal's GS-101  
Targeting the Complement Cascade  
Potentia Pharmaceutical's POT-4  
Roche/Genentech's Anti-Factor D  
Ophthotech's ARC1905  
Alexion Pharmaceuticals' Eculizumab  
Other Complement Inhibitors  
Neuroprotection  
Neurotech Pharmaceutical's NT-501  
Alcon's Tandospirone  
Allergan's Brimonidine  
Pfizer's RN6G  
Other Neuroprotective Agents  
Modulating the Visual Cycle  
Acucela's ACU-4429  
ReVision Therapeutics' Fenretinide  
QLT's QLT091001  
Pharmacologic Vitreolysis  
ThromboGenics' Microplasma  
Other Mechanisms of Action  
CoMentis' Mecamylamine  
Fovea Pharmaceuticals/  
Sanofi-Aventis' FOV2302  
Lpath's iSONEP  
Lpathomab  
MacuCLEAR's MC-1101  
Ophthotech's E10030 and Volociximab  
Other Pharmaceuticals' OT-551  
Resolvix' RX-10045  
RX-10001 & RX-20001  
Gene Therapies  
Targeted Genetics' RPE65 Gene  
Applied Genetic Technologies' rAAV2-CB-hRPE65  
Other Gene Therapies  
Stem Cell Therapies  
Potential Retinal Therapeutics Currently Marketed for Non-Retinal Indications  
Sustained Delivery Approaches  
Investigational Sustained-Release Technologies

Sustained-Release Corticosteroids  
Alimera Sciences/pSivida's Iluvien (formerly Medidur)  
I-vation TA  
Cortject  
Development Projects Terminated or With Questionable Futures  
Perceiva (sirolimus) from MacuSight  
Jerini Ophthalmic's JSM 6427, JPE-1375, and JSM-7717  
OPKO Health's Bevasiranib  
TG100801 from TargeGen  
Vatalanib from Novartis  
Allergan's AGN-745  
Vitreoretinal Technologies' Vitreosolve  
Summary Tables on Retinal Pharma Pipeline

## GLOBAL MARKET FORECASTS

Global Retina Pharmaceuticals Market by Region  
Forecast for the US  
Forecast for Europe  
Forecast for Japan  
Forecast for Other Wealthy Nations  
Forecast for China  
Forecast for India  
Forecast for Latin America  
Forecast for Rest of the World  
FUTURE NON-PHARMACOLOGIC THERAPIES  
New Non-Pharmacologic Therapeutic Approaches  
VisionCare's Implantable Miniature Telescope  
Therapeutic Radiation with NeoVista's  
Epi-Rad90 Brachytherapy  
Ellex' Retinal Regeneration Therapy or 2RT  
NovaVision's Vision Restoration Therapy  
Retinal Prosthesis Projects

## FINDINGS ON VITAMINS AND OTHER NUTRIENTS

AREDS I  
AREDS II

## COMPANY PROFILES

Acucela Inc.  
Adeona Pharmaceuticals  
Alcon, Inc.  
Alexion Pharmaceuticals  
Alimera Sciences  
Allergan, Inc.  
Applied Genetics Technologies, Inc.  
Bausch & Lomb  
Ceregene, Inc.  
Chengdu Kanghong Biotech Co., Ltd.  
CoMentis, Inc.  
Eyeteq Inc.  
Genzyme  
GlaxoSmithKline plc  
iCo Therapeutics  
Inotek Pharmaceuticals  
ISTA Pharmaceuticals  
Lpath, Inc.  
Lux Biosciences  
MacuClear, Inc.  
NeoVista, Inc.  
Neurotech Pharmaceuticals, Inc.  
Novagali Pharma  
Novartis International AG  
OcuCure Therapeutics  
OxiGene  
Ophthotech Corporation  
OPKO Health, Inc.  
Othera Pharmaceuticals Inc.  
Paloma Pharmaceuticals  
Pfizer Inc.  
Potentia Pharmaceuticals, Inc.  
pSivida Limited  
QLT Inc.  
Quark Pharmaceuticals, Inc.  
Regeneron Pharmaceuticals, Inc.  
Resolvix Pharmaceuticals  
ReVision Therapeutics, Inc.  
Roche/Genentech, Inc.  
Sanofi-Aventis, SA  
Silence Therapeutics, plc.  
SurModics, Inc.  
Taligen Therapeutics  
Targeted Genetics Corp.  
ThromboGenics NV  
Other Companies

Our **2010 Comprehensive Report on the Global Retinal Pharmaceutical Market** was published in October 2010. The report is printed in color and spiral bound for easy reading. The price of the 2010 report is \$5,000. An electronic PDF copy and/or additional paper copies are available for use within your company for an additional \$500 and \$300, respectively.